A new study by Pfizer and its partner BioNTech shows their COVID-19 vaccine is over 90% effective in children ages 5-11 as the companies seek an emergency use authorization.

The Food and Drug Administration released a briefing document Friday showing the vaccine, which received full approval for people 16 and older in August and an emergency use authorization for those ages 12-15, was 90.7% effective against symptomatic COVID-19 when the two-dose regimen was administered to children ages 5-11.

Recommended Stories

COVID-19 vaccine maker BioNTech expects updated omicron-specific shots by October

Goal is to have enough vaccines for every American by second quarter, Azar says after Moderna announcement

Moderna COVID-19 vaccine receives full FDA approval for adults